In the first two months of 2018, drugmakers raised their average price by 6.6%. However, it was a different story in January and February. There were no increases at all during those two months. that may mean that prices are stabilizing now or companies didn’t want to raise prices too much in the wintertime because people might be more likely to buy medications then.,
The “prescription price increase 2021” is a recent trend that has been taking place. Drugmakers have raised prices by 6.6% on average early this year, which will only continue to rise in the years to come.
Drugmakers boosted list prices for cancer, diabetes, and other prescription drugs by an average of 6.6 percent in the first few weeks of this year, keeping to relatively modest hikes while legislators review pricing practices.
According to a study by Rx Savings Solutions, which provides software to assist companies and health plans select the least-expensive prescriptions, around 150 drugmakers hiked prices on 866 items in the United States between January 20 and January 20.
During the first few weeks of a new year, drugmakers often hike the pricing of their drugs.
Many drugmakers committed to restrain price rises after adopting double-digit hikes some years ago in response to political pressure and the threat of Congress enacting rules to limit their pricing power.
Because of the discounts they give to health insurers and pharmacy-benefit managers, the organizations that supervise prescription plans for employers, many corporations claim they don’t reap all or any of the advantages from price hikes.
Drugmakers were more aggressive in raising prices in the past, particularly in 2015 and 2016, when some marquee drugs had increases of greater than 10%, said Ronny Gal, a pharmaceutical industry analyst at Bernstein & Co.
“Those were the years when the firms went crazy with price hikes,” Mr. Gal said. “It was the pinnacle.”
Several elements in President Biden’s social-spending and climate measure would limit drugmakers’ pricing power.
Michael Brochstein/Zuma Press/Zuma Press/Zuma Press/Zuma Press/Zuma Press
The price hikes drew condemnation from both Republicans and Democrats, and congressional hearings were held as a result.
Apart from political pressure, firms have been less brave in increasing prices since it is less lucrative than in previous years due to several drug-pricing regulations aimed to limit inflation, according to Mr. Gal.
Many pharmacy benefit managers have negotiated price increases limits, which force drugmakers to pay rebates on product sales that exceed specific levels.
Mr. Gal also noted that Medicaid, the state-federal health-insurance program for the poor that forces corporations to pay rebates on any price rises over inflation, has grown in importance.
Several drug-price measures in the Biden administration’s social-spending and climate plan, which is presently stuck in Congress, would limit drugmakers’ pricing power.
The plan would set a ceiling on price rises across both government and commercial health insurance systems at the rate of inflation, and it would force the government to actively negotiate pricing for some high-cost pharmaceuticals covered by Medicare.
“We know that individuals are more financially stressed now than they were a year ago, and the need for information and help is growing,” said Michael Rea, CEO of Rx Savings Solutions.
Humira, AbbVie’s anti-inflammatory medicine, has been hiked by 7% in price.
Photo courtesy of The Wall Street Journal’s Joe Buglewicz
According to the Rx Savings Solutions report, the average rise of 6.6 percent did not include increases to various dosages for the same prescription. According to the data, drugmakers hiked prices on 893 medications by an average of 4.5 percent during the same time last year.
This year, prices for some of the most popular drugs in the United States increased, including many that cost tens of thousands of dollars per year.
AbbVie Inc. raised the price of its anti-inflammatory drug Humira by 7%; Bristol-Myers Squibb Co. raised the price for blood-thinner Eliquis, which it co-markets with Pfizer Inc., by 6%; and Eli Lilly & Co. raised the price of its diabetes medicine Trulicity by 5%.
AbbVie did not respond to a request for comment. A representative for Bristol-Myers said that the company anticipates its net pricing to stay stable in 2022, that its “list prices remain below inflation,” and that the increases were limited to drugs undergoing clinical trials. Lilly’s price hikes “were on average lower than industry rivals with medications in comparable therapeutic areas,” according to a spokesman.
There were some significant price hikes. Blue Point Laboratories, a generic medication vendor owned by AmerisourceBergen Corp., has more than quadrupled the price of the cancer chemotherapy drug cisplatin to $30. Blue Point buys generic pharmaceuticals from manufacturers and sells them under its own brand name, according to an Amerisource representative, and its list price “mirrors and is tethered to” the list price established by its supplier.
Exelan Pharmaceuticals Inc. increased the price of its generic lisinopril to treat high blood pressure from $6.17 to $549.85, depending on the dose and package size.
Pfizer increased the price of its Prevnar vaccinations, which protect against bacterial illnesses, by 6.9%.
Bloomberg News/Bloomberg/Daniel Acker
According to Exelan President Brian Christensen, the price increase is merely a placeholder and does not represent the amount that buyers would pay. According to him, Exelan exclusively sells pharmaceuticals to government entities, who pay a defined fee under a national contract.
Pfizer increased the cost of 219 medications by an average of 3.2 percent. Increases were much greater on some of the company’s best-selling items.
Ibrance, a cancer medicine sold for $2.5 billion in the United States through the third quarter of last year, had a 6.9% increase in price. Prevnar vaccinations, which protect against bacterial infections and totaled $2.1 billion in U.S. sales through the third quarter, also had a 6.9% price increase.
The price of Pfizer’s rheumatoid arthritis medicine Xeljanz, which had $1.1 billion in sales in the third quarter, increased by 5.5 percent.
“Our net pricing—the prices we actually get for our medications—have declined over the last three years owing to increasing rebates and discounts provided to insurance companies and pharmacy benefit managers,” Pfizer stated.
Novartis AG, a Swiss pharmaceutical company, hiked prices on 17 medications by an average of 5.7 percent. Cosentyx, a psoriasis therapy with $2.1 billion in U.S. sales through the third quarter of last year, and Entresto, a heart-failure medicine with $1.2 billion in U.S. sales over the same time, both saw a 7% price hike.
LET US KNOW WHAT YOU’RE CONCERNED ABOUT.
Do you believe that prescription medicine costs are too high? If that’s the case, what’s the greatest strategy to bring them down? Participate in the discussion below.
Only 4% of Novartis’ product portfolio in the United States would see price increases, according to a Novartis representative. “We estimate the average net price increase to be much less across our portfolio after considerable reductions and rebates granted to commercial and government payers,” the spokesperson added.
Gilead Sciences Inc., a developer of infectious-disease medications, hiked prices 5.6 percent across 11 products, including HIV blockbusters Biktarvy ($4.9 billion in US sales through the third quarter of last year) and Genvoya ($1.6 billion in US sales through the third quarter of last year).
The price hikes were made “after a careful examination of how best to pursue novel treatment alternatives to meet unmet medical need while maintaining affordability and availability for the people we serve,” according to a Gilead spokesperson. According to the spokeswoman, the business anticipates net pricing of its HIV medications to fall due to higher rebates and discounts.
Joseph Walker can be reached at [email protected]
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
The “why did my prescription price go up 2021” is a question that many people have been asking. Drugmakers raised prices by 6.6% on average early this year, but the cause of the increase remains unclear.
Related Tags
- drug retail price list 2021
- list of drug price increases 2021
- list of price increases 2021
- eliquis price increase 2021
- big pharma raising drug prices
